Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.77 USD | +3.21% | +1.25% | +33.21% |
02:38pm | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
May. 09 | Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.21% | 279M | C- | ||
+17.43% | 124B | B+ | ||
+15.47% | 109B | B+ | ||
-6.95% | 23.84B | B+ | ||
+2.13% | 22.42B | B | ||
-14.29% | 17.5B | A- | ||
-10.06% | 16.61B | B | ||
-37.63% | 16.43B | A- | ||
+2.00% | 13.4B | C+ | ||
+26.60% | 11.47B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XOMA Stock
- Ratings XOMA Corporation